AI-generated · cited to primary sources · not investment advice · How we research
Quick Heal Tech
Our verdict on Quick Heal Tech isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company confirmed the receipt of its first order for Seqrite Data Privacy during the period. (2 met across 2 tracked commitments)
“And like I said, some of the organizations who are forward looking are not waiting for the act to come in. And we are already doing multiple POCs and proposals are there, hopefully we will be able to close more deals this quarter as well.”
Management has successfully maintained its market leadership with a share of over 30% in the Indian market. (2 met, 1 in progress across 3 tracked commitments)
“Market leadership with over 30% in the Indian market ... Focus towards maintaining our market share in AV segment”
See the full cited Management analysis of Quick Heal Tech
How durable is the business?
The Enterprise segment has reached revenue parity with the Consumer segment, now contributing 50% of total revenue. While gross revenue for the quarter (₹31.7 Cr) showed a slight YoY decline of 2.3%, the segment's share of the total business has expanded significantly from 40% in FY25. (4 expanding)
“Deconstructing Current Business... FY 2025: 40% Enterprise; Q1 FY 2026: 50% Enterprise”
The enterprise segment faced headwinds with flattish year-on-year results due to deferred deal closures, though the order book remains healthy at Rs. 24 crores. (1 stable, 4 expanding)
“In the enterprise segment, we have seen deferral in few deal closures, resulting in a flattish year-on-year result.”
See the full cited Business Model analysis of Quick Heal Tech
Where does growth come from?
The company's addressable market is expanding rapidly as it moves into higher customer segments and launches niche products, with a projected 3.6x increase in market size over 4 years. (5 accelerating across 5 signals)
“Evolution of Serviceable Operatable Market ... FY 23 1100 Cr ... FY 26 3500 Cr ... FY 27 4000 Cr”
The transition to cloud-based services within the enterprise segment is accelerating, showing a consistent upward trajectory in the revenue mix. (5 accelerating across 5 signals)
“Deconstructing CURRENT BUSINESS ... FY 2021 20% Enterprise ... FY 2026 51% Enterprise”
See the full cited Future Growth analysis of Quick Heal Tech
What could break the thesis?
The company remains loss-making with a PAT of negative Rs. 5.5 crore this quarter. While revenue fell, operating costs remained flat at Rs. 66 crores, leading to continued bottom-line pressure. (1 stable, 1 intensifying, 2 easing, 1 high-severity)
“EBITDA % -60.2%”
Management took the drastic step of stopping sales (curtailing invoicing) to specific partners due to overdue receivables. While they saw a positive trend in July, the proactive restriction of sales to manage credit risk confirms the severity of the collection issue. (5 intensifying, 2 high-severity)
“Consumer Revenue -71.9% YoY”
See the full cited Risk analysis of Quick Heal Tech
Read the full thesis on Quick Heal Tech
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.